FR21C1051I1 - Nouveau sel hydrogenosulfate - Google Patents

Nouveau sel hydrogenosulfate

Info

Publication number: FR21C1051I1
Authority: FR; France
Prior art keywords: hydrogenosulfate; salt; new; new hydrogenosulfate; hydrogenosulfate salt
Prior art date: 2005-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1051C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Array Biopharma Inc

Original Assignee

AstraZeneca AB

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2021-11-05

Publication date

2021-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1051(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-11-05 Application filed by AstraZeneca AB, Array Biopharma Inc filed Critical AstraZeneca AB

2021-12-24 Publication of FR21C1051I1 publication Critical patent/FR21C1051I1/fr

2023-02-17 Application granted granted Critical

2023-02-17 Publication of FR21C1051I2 publication Critical patent/FR21C1051I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Cosmetics (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Detergent Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

FR21C1051C 2005-12-21 2021-11-05 Nouveau sel hydrogenosulfate Active FR21C1051I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US75278105P	2005-12-21	2005-12-21
PCT/US2006/061895 WO2007076245A2 (fr)	2005-12-21	2006-12-12	Nouveau sel hydrogenosulfate

Publications (2)

Publication Number	Publication Date
FR21C1051I1 true FR21C1051I1 (fr)	2021-12-24
FR21C1051I2 FR21C1051I2 (fr)	2023-02-17

Family

ID=38218759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1051C Active FR21C1051I2 (fr)	2005-12-21	2021-11-05	Nouveau sel hydrogenosulfate

Country Status (32)

Country	Link
US (4)	US20100016393A1 (fr)
EP (1)	EP1968948B1 (fr)
JP (1)	JP5127723B2 (fr)
KR (1)	KR101361460B1 (fr)
CN (2)	CN101360718B (fr)
AR (1)	AR058696A1 (fr)
AU (1)	AU2006330759B2 (fr)
BR (1)	BRPI0620091B1 (fr)
CA (1)	CA2634149C (fr)
CY (2)	CY1114303T1 (fr)
DK (1)	DK1968948T3 (fr)
EC (1)	ECSP088597A (fr)
ES (1)	ES2421746T3 (fr)
FI (1)	FIC20210043I1 (fr)
FR (1)	FR21C1051I2 (fr)
HR (1)	HRP20130663T1 (fr)
HU (1)	HUS2100046I1 (fr)
IL (1)	IL192224A (fr)
LT (1)	LTC1968948I2 (fr)
LU (1)	LUC00234I2 (fr)
MX (1)	MX2008008298A (fr)
MY (1)	MY157733A (fr)
NL (1)	NL301139I2 (fr)
NZ (1)	NZ569792A (fr)
PL (1)	PL1968948T3 (fr)
PT (1)	PT1968948E (fr)
RS (1)	RS52843B (fr)
SI (1)	SI1968948T1 (fr)
TW (1)	TWI405756B (fr)
UA (1)	UA93531C2 (fr)
WO (1)	WO2007076245A2 (fr)
ZA (1)	ZA200805705B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2478374C (fr)	2002-03-13	2009-01-06	Eli M. Wallace	Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US20100004247A1 (en) *	2007-12-12	2010-01-07	Astrazeneca Ab	Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
SA109300195B1 (ar) *	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
WO2011095807A1 (fr)	2010-02-07	2011-08-11	Astrazeneca Ab	Combinaisons d'inhibiteurs de mek et de hh
WO2012145503A1 (fr) *	2011-04-21	2012-10-26	Novartis Ag	Combinaisons pharmaceutiques
MX350957B (es)	2011-11-23	2017-09-27	Medimmune Llc	Moleculas de union especificas para her3 y usos de las mismas.
WO2013109142A1 (fr)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
AR099630A1 (es) *	2012-10-19	2016-08-10	Novartis Ag	Preparación de un inhibidor de mek y formulación que lo comprende
EP3342770B1 (fr)	2013-03-06	2022-03-30	AstraZeneca AB	Inhibiteurs de quinazoline pour activer des formes mutantes du récepteur du facteur de croissance épidermique
EP3046557A1 (fr)	2013-09-20	2016-07-27	Stichting Het Nederlands Kanker Instituut	Association de rock et de la voie mapk
WO2015041534A1 (fr)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk en combinaison avec raf/erk/mek
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (fr)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions pour le traitement du cancer
CN105566327A (zh) *	2014-10-09	2016-05-11	江苏恒瑞医药股份有限公司	一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
EP3355923B1 (fr)	2015-10-01	2022-02-23	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Inhibiteurs de l'histone désacétylase utilisables dans le traitement d'un mélanome résistant aux médicaments
BR112018003232A2 (pt)	2015-10-06	2018-09-25	Redhill Biopharma Ltd	terapias de combinação para tratamento de câncer
WO2017099591A1 (fr)	2015-12-07	2017-06-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Traitement de cancers à mutation braf résistants aux inhibiteurs
WO2017204626A1 (fr)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Polythérapie combinant map2k4/map3k1 et une inhibition de mek/erk
CN109438362B (zh)	2017-11-14	2020-07-21	深圳市塔吉瑞生物医药有限公司	一种取代的苯并咪唑化合物及包含该化合物的组合物
CA3117559C (fr) *	2018-10-31	2023-09-26	Les Laboratoires Servier	Sel d'hydrogenosulfate d'un inhibiteur de bcl-2, forme cristalline connexe, methode de preparation et compositions pharmaceutiques les comprenant
US12175741B2 (en) *	2021-06-22	2024-12-24	Intrinsic Innovation Llc	Systems and methods for a vision guided end effector
EP4536226A1 (fr) *	2022-06-06	2025-04-16	Alivus Life Sciences Limited	Procédé de préparation de sélumétinib et de sels de celui-ci
US20240400519A1 (en) *	2023-06-01	2024-12-05	Chunghwa Chemical Synthesis & Biotech Co. Ltd.	Crystal forms a, b, c, d, e, f and g of selumetinib sulfate and preparation methods thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (fr)	1995-04-20	2001-07-24	Pfizer Inc.	Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
KR20000067904A (ko)	1996-07-18	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	매트릭스 메탈로프로테아제의 포스피네이트계 억제제
BR9711223A (pt)	1996-08-23	1999-08-17	Pfizer	Derivados de cido arilsulfonilamino-hidrox mico
EP0950059B1 (fr)	1997-01-06	2004-08-04	Pfizer Inc.	Derives de sulfone cyclique
IL131042A0 (en)	1997-02-03	2001-01-28	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt)	1997-02-07	2000-03-08	Pfizer	Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
KR20000070923A (ko)	1997-02-11	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐 하이드록삼산 유도체
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
CA2478374C (fr) *	2002-03-13	2009-01-06	Eli M. Wallace	Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
ATE380027T1 (de)	2003-09-09	2007-12-15	Fumapharm Ag	Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
SA109300195B1 (ar) *	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان

2006
- 2006-12-04 TW TW095144927A patent/TWI405756B/zh active
- 2006-12-12 EP EP06840192.6A patent/EP1968948B1/fr active Active
- 2006-12-12 NZ NZ569792A patent/NZ569792A/en unknown
- 2006-12-12 CN CN2006800514795A patent/CN101360718B/zh active Active
- 2006-12-12 PL PL06840192T patent/PL1968948T3/pl unknown
- 2006-12-12 CA CA2634149A patent/CA2634149C/fr active Active
- 2006-12-12 PT PT68401926T patent/PT1968948E/pt unknown
- 2006-12-12 DK DK06840192.6T patent/DK1968948T3/da active
- 2006-12-12 KR KR1020087017543A patent/KR101361460B1/ko active Active
- 2006-12-12 BR BRPI0620091-5A patent/BRPI0620091B1/pt active IP Right Grant
- 2006-12-12 CN CN2011102355739A patent/CN102329270A/zh active Pending
- 2006-12-12 ES ES06840192T patent/ES2421746T3/es active Active
- 2006-12-12 UA UAA200808839A patent/UA93531C2/ru unknown
- 2006-12-12 JP JP2008547679A patent/JP5127723B2/ja active Active
- 2006-12-12 AU AU2006330759A patent/AU2006330759B2/en active Active
- 2006-12-12 MX MX2008008298A patent/MX2008008298A/es active IP Right Grant
- 2006-12-12 US US12/097,942 patent/US20100016393A1/en not_active Abandoned
- 2006-12-12 MY MYPI20082207A patent/MY157733A/en unknown
- 2006-12-12 WO PCT/US2006/061895 patent/WO2007076245A2/fr not_active Ceased
- 2006-12-12 HR HRP20130663TT patent/HRP20130663T1/hr unknown
- 2006-12-12 RS RS20130295A patent/RS52843B/sr unknown
- 2006-12-12 SI SI200631619T patent/SI1968948T1/sl unknown
- 2006-12-20 AR ARP060105662A patent/AR058696A1/es not_active Application Discontinuation
2008
- 2008-06-16 IL IL192224A patent/IL192224A/en active IP Right Grant
- 2008-06-30 ZA ZA2008/05705A patent/ZA200805705B/en unknown
- 2008-07-02 EC EC2008008597A patent/ECSP088597A/es unknown
2012
- 2012-05-03 US US13/463,499 patent/US9156795B2/en active Active
2013
- 2013-07-11 CY CY20131100590T patent/CY1114303T1/el unknown
2014
- 2014-01-10 US US14/152,766 patent/US20140221443A1/en not_active Abandoned
2015
- 2015-04-28 US US14/698,151 patent/US9562017B2/en active Active
2021
- 2021-10-25 HU HUS2100046C patent/HUS2100046I1/hu unknown
- 2021-10-26 CY CY2021030C patent/CY2021030I1/el unknown
- 2021-10-27 LU LU00234C patent/LUC00234I2/fr unknown
- 2021-10-27 NL NL301139C patent/NL301139I2/nl unknown
- 2021-11-05 FR FR21C1051C patent/FR21C1051I2/fr active Active
- 2021-11-26 LT LTPA2021530C patent/LTC1968948I2/lt unknown
- 2021-11-26 FI FIC20210043C patent/FIC20210043I1/fi unknown

Also Published As

Publication number	Publication date
CA2634149C (fr)	2013-08-13
FR21C1051I2 (fr)	2023-02-17
LTPA2021530I1 (fr)	2021-12-27
US9156795B2 (en)	2015-10-13
CY2021030I2 (el)	2022-03-24
CN102329270A (zh)	2012-01-25
LTC1968948I2 (fr)	2023-07-10
CN101360718B (zh)	2012-01-11
HUS2100046I1 (hu)	2021-11-29
NL301139I2 (nl)	2022-02-22
NL301139I1 (fr)	2021-11-03
HK1124043A1 (en)	2009-07-03
BRPI0620091A2 (pt)	2011-11-01
AU2006330759A1 (en)	2007-07-05
FIC20210043I1 (fi)	2021-11-26
IL192224A (en)	2014-08-31
CY2021030I1 (el)	2022-03-24
JP2009521487A (ja)	2009-06-04
AR058696A1 (es)	2008-02-20
TW200800915A (en)	2008-01-01
UA93531C2 (en)	2011-02-25
US20160024018A1 (en)	2016-01-28
SI1968948T1 (sl)	2013-08-30
CN101360718A (zh)	2009-02-04
PT1968948E (pt)	2013-07-25
US20140221443A1 (en)	2014-08-07
ES2421746T3 (es)	2013-09-05
DK1968948T3 (da)	2013-08-26
LUC00234I2 (fr)	2025-02-03
BRPI0620091B1 (pt)	2024-04-30
EP1968948A2 (fr)	2008-09-17
ECSP088597A (es)	2008-08-29
KR101361460B1 (ko)	2014-02-10
MY157733A (en)	2016-07-15
WO2007076245A2 (fr)	2007-07-05
NZ569792A (en)	2011-01-28
MX2008008298A (es)	2008-09-24
US20120253049A1 (en)	2012-10-04
CA2634149A1 (fr)	2007-07-05
US20100016393A1 (en)	2010-01-21
US9562017B2 (en)	2017-02-07
IL192224A0 (en)	2009-02-11
TWI405756B (zh)	2013-08-21
AU2006330759B2 (en)	2012-12-06
PL1968948T3 (pl)	2013-10-31
JP5127723B2 (ja)	2013-01-23
EP1968948A4 (fr)	2010-12-15
RS52843B (sr)	2013-12-31
KR20080080200A (ko)	2008-09-02
ZA200805705B (en)	2012-09-26
WO2007076245A3 (fr)	2008-01-24
HRP20130663T1 (xx)	2013-08-31
CY1114303T1 (el)	2016-08-31
EP1968948B1 (fr)	2013-05-22

Publication	Publication Date	Title
FR21C1051I2 (fr)	2023-02-17	Nouveau sel hydrogenosulfate
NO2021013I1 (no)	2021-03-23	filgotinib or a salt thereof
NL300885I2 (nl)	2022-02-24	Irinotecansucrosofaatzout
EP2022793A4 (fr)	2010-09-08	Nouveau composé hétérocyclique et sel et intermédiaire correspondants
EP1900732A4 (fr)	2009-11-18	Nouveau composé hétérocyclique azoté et sel de celui-ci
ATE463485T1 (de)	2010-04-15	Piperazinverbindungen mit herbizider wirkung
EP2098517A4 (fr)	2012-02-15	Nouveau dérivé de phényl-isoxazol-3-ol
ATE502948T1 (de)	2011-04-15	Substituierte bicyclolactamverbindungen
DK1919907T3 (da)	2011-04-18	Heterocyklisk forbindelse
EP2305641A4 (fr)	2012-08-22	Composé de sulfonamide ou sel de celui-ci
EP2186799A4 (fr)	2013-05-15	Composé de sel de sulfonium aromatique
BRPI0807004A2 (pt)	2014-04-15	Sal
EP2114132A4 (fr)	2011-03-23	Moulinet de pêche
EP2062902A4 (fr)	2010-11-17	Sel de lithium
DK1937650T3 (da)	2011-10-03	Heterocykliske forbindelser
EP1944301A4 (fr)	2012-01-04	Nouveau derive de benzoxathiine
ATE443056T1 (de)	2009-10-15	Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
DE602008000563D1 (de)	2010-03-11	Angelspule
DE602008006282D1 (de)	2011-06-01	Angelrolle
ATE518827T1 (de)	2011-08-15	Aliskiren-nitratsalz
FI7694U1 (fi)	2007-11-30	Viehe
SE530154C8 (sv)	2008-04-08	Saltblandning
ATE474459T1 (de)	2010-08-15	Angelrute
DK2280691T3 (da)	2022-10-31	Krystallinsk DOPC
FR2885162B1 (fr)	2009-02-27	Nouveau type de volet.